Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Mizue Terai"'
Autor:
Masanori Ozaki, Ken Kageyama, Kenjiro Kimura, Shinpei Eguchi, Akira Yamamoto, Ryota Tanaka, Takehito Nota, Hiroki Yonezawa, Hideyuki Nishiofuku, Yuki Sakai, Naoki Tani, Atsushi Jogo, Mizue Terai, Takami Sato, Takeaki Ishizawa, Yukio Miki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Liver metastases from pancreatic ductal adenocarcinoma (PDAC) are highly fatal. A rat-based patient-derived tumor xenograft (PDX) model is available for transcatheter therapy. This study aimed to create an immunodeficient rat model with live
Externí odkaz:
https://doaj.org/article/a062ad6132a74f5f94005ead20d308ed
Autor:
Anna Han, Dzmitry Mukha, Vivian Chua, Timothy J. Purwin, Manoela Tiago, Bhavik Modasia, Usman Baqai, Jenna L. Aumiller, Nelisa Bechtel, Emily Hunter, Meggie Danielson, Mizue Terai, Philip B. Wedegaertner, Takami Sato, Solange Landreville, Michael A. Davies, Stefan Kurtenbach, J. William Harbour, Zachary T. Schug, Andrew E. Aplin
Publikováno v:
Cancers, Vol 15, Iss 13, p 3451 (2023)
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression sig
Externí odkaz:
https://doaj.org/article/bd1520908be04ad1b023ec228e9a8999
Autor:
Emilie Lalonde, PhD, Kathryn Ewens, PhD, Jennifer Richards-Yutz, MS, Jessica Ebrahimzedeh, MS, Mizue Terai, PhD, Carin F. Gonsalves, MD, Takami Sato, PhD, MD, Carol L. Shields, MD, Arupa Ganguly, PhD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 2, Pp 100121- (2022)
Purpose: To evaluate the clinical relevance of low-frequency copy number aberrations (CNAs) in uveal melanoma (UM) and to discern residual genomic and clinical heterogeneity within established molecular subtypes based on genome-wide CNA profiling of
Externí odkaz:
https://doaj.org/article/10b3f894e2074e7c9121e87ed795b0f6
Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma
Autor:
Takahito Sugase, Bao Q. Lam, Meggie Danielson, Mizue Terai, Andrew E. Aplin, J. Silvio Gutkind, Takami Sato
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-14 (2020)
Abstract Background Patients with metastatic uveal melanoma (MUM) in the liver usually die within 1 year. The development of new treatments for MUM has been limited by the lack of diverse MUM cell lines and appropriate animal models. We previously re
Externí odkaz:
https://doaj.org/article/40fa013f54d94e7fa6ce82bad4dece46
Autor:
Mizue Terai, Ayako Shimada, Inna Chervoneva, Liam Hulse, Meggie Danielson, Jeff Swensen, Marlana Orloff, Philip B. Wedegaertner, Jeffrey L. Benovic, Andrew E. Aplin, Takami Sato
Publikováno v:
Cancers, Vol 13, Iss 22, p 5749 (2021)
Uveal melanoma is the most common primary ocular malignancy in adults, characterized by gene mutations in G protein subunit alpha q (GNAQ) and G protein subunit alpha 11 (GNA11). Although they are considered to be driver mutations, their role in MUM
Externí odkaz:
https://doaj.org/article/86a4c271f81742bab04b74ded1bf5119
Publikováno v:
Cancers, Vol 13, Iss 21, p 5457 (2021)
Hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signaling promotes tumorigenesis and tumor progression in various types of cancer, including uveal melanoma (UM). The roles of HGF/MET signaling have been studied in cell s
Externí odkaz:
https://doaj.org/article/6201554d294145c1a447b4a4b4fe1ca2
Autor:
Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N. Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J. Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson, Meenhard Herlyn
Publikováno v:
Cell Reports, Vol 21, Iss 7, Pp 1953-1967 (2017)
Summary: Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitat
Externí odkaz:
https://doaj.org/article/3165039b88f34a199db1a3519c05d121
Autor:
Masahiro Ohara, Kengo Saito, Ken Kageyama, Mizue Terai, Hanyin Cheng, Andrew E. Aplin, Takami Sato
Publikováno v:
Cancers, Vol 13, Iss 5, p 1104 (2021)
Uveal melanoma (UM) is the most common cancer of the eye in adults. Up to 50% of UM patients subsequently develop metastases, especially in the liver. It has been reported that the retinoblastoma (RB) pathway is deregulated in more than 90% of UM des
Externí odkaz:
https://doaj.org/article/086646f305cb4baaae8c4198e68ff30b
Autor:
Ken Kageyama, Masahiro Ohara, Kengo Saito, Shinji Ozaki, Mizue Terai, Michael J. Mastrangelo, Paolo Fortina, Andrew E. Aplin, Takami Sato
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-19 (2017)
Abstract Background Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis within 1 year. A major drawback in the development of new treatments for metastatic uveal melanoma is the difficulty in obtaining
Externí odkaz:
https://doaj.org/article/fee483d021fb42bbabf7d2e51c39de4c
Autor:
Vivian Chua, Marlana Orloff, Jessica LF Teh, Takahito Sugase, Connie Liao, Timothy J Purwin, Bao Q Lam, Mizue Terai, Grazia Ambrosini, Richard D Carvajal, Gary Schwartz, Takami Sato, Andrew E Aplin
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 2, Pp n/a-n/a (2019)
Abstract Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX511
Externí odkaz:
https://doaj.org/article/ad9494b5987a443bb7fdef74004cf81b